Guardion Health Sciences Receives Initial Order from Malaysian Company for Exclusive Immuno-Supportive Formula
April 01 2020 - 7:00AM
Guardion Health Sciences, Inc. (“Guardion” or the “Company”)
(Nasdaq: GHSI), a company (i) that has developed medical foods and
medical devices in the ocular health marketplace and (ii) that is
developing nutraceuticals that the Company believes will provide
health benefits to consumers, announced today that it received an
initial order from Astramune Sdn Bhd, a subsidiary of Ho Wah
Genting Berhad (“HWGB”) (KLSE: 9601), a Malaysian company listed on
the Malaysian Stock Exchange (Industrial Products sector), for a
sample order of its proprietary immuno-supportive formula. Guardion
currently anticipates shipping this sample order by June 30, 2020.
The Company had previously announced in February
2020 that HWGB contracted Guardion and its wholly-owned subsidiary,
NutriGuard, to develop an immuno-supportive formula for the HWGB
consumer base. Dr. Mark McCarty, the original founder of
NutriGuard, and now a senior scientist/consultant to Guardion, has
led the development of this proprietary formulation.
Michael Favish, CEO of Guardion Health Sciences,
commented, “We were pleased to have been selected by HWGB to
utilize our expertise and resources to develop a proprietary
product that is specifically designed to boost immune system
capability. Given the demand expected from HWGB’s customer base, we
are advised that HWGB is ramping up this business line, and we are
preparing to be able to meet HWGB’s product requirements during
2020 and thereafter.”
Dr. McCarty is a leader in the scientific
validation of nutrition-based therapies for potentiating the type 1
interferon response to RNA viruses. The formula is designed to
provide immuno-supportive benefits to its users. The formulation
has not been used or tested for, nor is it intended to specifically
address, symptoms of the coronavirus (COVID-19).
About NutriGuardTM
NutriGuardTM formulates
high-quality nutraceuticals, which are designed to supplement
consumers’ diets. NutriGuard uses industry standards to establish
the safety and efficacy of the products it develops and markets,
maintains that commitment through prudent manufacturing and quality
assurance programs, and only uses manufacturers who comply with FDA
current Good Manufacturing Practices (cGMP) requirements. Guardion
plans to increase NutriGuard’s existing customer base and build on
its product platform by making NutriGuard products available to
patients directly and through recommendations by their
physicians.
About Guardion Health Sciences, Inc.
Guardion is a specialty health sciences company
(i) that has developed medical foods and medical devices in the
ocular health marketplace and (ii) that is developing
nutraceuticals that the Company believes will provide medicinal and
health benefits to consumers. Information and risk factors with
respect to Guardion and its business, including its ability to
successfully develop and commercialize its proprietary products and
technologies, may be obtained in the Company’s filings with the SEC
at www.sec.gov.
Forward-Looking Statement Disclaimer
With the exception of the historical information
contained in this news release, the matters described herein may
contain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Statements
preceded by, followed by or that otherwise include the words
“believes,” “expects,” “anticipates,” “intends,” “projects,”
“estimates,” “plans” and similar expressions or future or
conditional verbs such as “will,” “should,” “would,” “may” and
“could” are generally forward-looking in nature and not historical
facts, although not all forward-looking statements include the
foregoing. These statements involve unknown risks and uncertainties
that may individually or materially impact the matters discussed
herein for a variety of reasons that are outside the control of the
Company, including, but not limited to, the Company’s ability to
raise sufficient financing to implement its business plan, the
impact of the coronavirus (COVID-19) on the Company’s business and
the economy in general, and the Company’s ability to successfully
develop and commercialize its proprietary products and
technologies. Readers are cautioned not to place undue reliance on
these forward- looking statements, as actual results could differ
materially from those described in the forward-looking statements
contained herein. Readers are urged to read the risk factors set
forth in the Company’s filings with the SEC, which are available at
the SEC’s website (www.sec.gov). The Company disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Guardion Health Sciences, Inc.
15150 Avenue of Science, Ste. 200 San Diego, CA 92128Ph
858.605.9055; Fax 858.630.5543www.guardionhealth.com
Investor Relations Contact:Jenene Thomas JTC
Team, LLCTelephone: (833) 475-8247E-Mail: jtc@jtcir.com
Porter, LeVay & Rose, Inc.
Michael PorterTelephone: (212) 564-4700 E-mail:
mike@plrinvest.com
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Sep 2023 to Sep 2024